Previous 10 | Next 10 |
Genprex (NASDAQ: GNPX) today announced the exercise of warrants to purchase approximately 5.4 million shares of common stock issued in connection with capital raises in May 2018 and November 2019 with two institutional investors at a price of $0.46 per share, resulting in its receipt of appr...
Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX ), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, announced today that warrants to purchase approximately 5.4 million shares ...
Gainers: Portola Pharmaceuticals (NASDAQ: PTLA ) +130% . More news on: Portola Pharmaceuticals, Inc., CleanSpark, Inc., Genprex, Inc., Stocks on the move, , Read more ...
Portola Pharmaceuticals (NASDAQ: PTLA ) +131% on being acquired for $18/share. More news on: Portola Pharmaceuticals, Inc., SG Blocks, Inc., MicroVision, Inc., Stocks on the move, , Read more ...
May 5, 2020 Palm Beach, FL – May 5, 2020 – The global market for cancer therapies is projected to reach US$220. 5 billion by 2025, driven by the rise in cancer prevalence to epidemic proportions and the still ongoing search to find effective treatments for the diseas...
Nano cap Genprex (NASDAQ: GNPX ) jumps 39% premarket on robust volume in reaction to its agreement with MD Anderson Cancer Center for exclusive global rights to a portfolio of 16 patent applications and related technology for the treatment of cancer using TUSC2 gene therapy Onc...
New license agreement expands Genprex’s oncology franchise Licensed technologies include use of Genprex’s TUSC2 gene therapy combined with immunotherapy drugs, including: Pembrolizumab (Merck’s largest selling drug Keytruda®) Nivolumab (Bristol-Myer...
Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced its issuance of an April 2020 Shareholder Letter. According to the update, the letter highlights the Company’s progres...
Company provides updates on recent regulatory, clinical, operational, and business developments Fast Track Designation by FDA for Oncoprex™ in combination with osimertinib in non-small cell lung cancer emphasized Exclusive license agreement with University of Pittsburg...
Are These On Your Penny Stocks Watch List In 2020? I’m pretty sure that most people don’t think about penny stocks and analyst ratings at first. From what I’m sure many of you initially experienced, penny stocks have been known for volatile trading of “start-up...
News, Short Squeeze, Breakout and More Instantly...
Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, will be participating at two conferences during May. According to the announcement, Genprex CFO Ryan Confer will be presenting at the Sidoti Microcap...
Genprex to Present and Participate at Upcoming May Investor and Industry Conferences PR Newswire AUSTIN, Texas , May. 1, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developin...
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting PR Newswire Compelling Data Validates the Potential...